Patents by Inventor Harry Jefferson Leighton

Harry Jefferson Leighton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition and method for treating an autoimmune disease
    Patent number: 9901638
    Abstract: A combination of antibiotics including rifabutin, clarithromycin and clofazimine for the treatment of an autoimmune disease such as multiple sclerosis and related diseases. In a further aspect, there is provided a composition comprising a combination of two or more antibiotic agents for the treatment of an autoimmune disease, said two or more antibiotic agents selected from rifabutin, clofazimine, and at least one macrolide.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: February 27, 2018
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Patrick Laughlin McLean, Harry Jefferson Leighton
  • COMPOSITION AND METHOD FOR TREATING AN AUTOIMMUNE DISEASE
    Publication number: 20140228307
    Abstract: A combination of antibiotics including rifabutin, clarithromycin and clofazimine for the treatment of an autoimmune disease such as multiple sclerosis and related diseases. In a further aspect, there is provided a composition comprising a combination of two or more antibiotic agents for the treatment of an autoimmune disease, said two or more antibiotic agents selected from rifabutin, clofazimine, and at least one macrolide.
    Type: Application
    Filed: September 19, 2012
    Publication date: August 14, 2014
    Inventors: Reza Fathi, Patrick Laughlin McLean, Harry Jefferson Leighton
  • Treatment of CNS disorders using CNS target modulators
    Patent number: 7355042
    Abstract: The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: April 8, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot, James F. White, Michael Solomon, Kazumi Shiosaki
  • CNS target modulators
    Patent number: 7317026
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. More specifically, the invention is directed to derivatized, e.g., ester or carboxylic acid derivatized, doxepins, and analogs thereof, useful for the treatment of sleep disorders.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 8, 2008
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot
  • Treatment of sleep disorders using CNS target modulators
    Patent number: 7189757
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: March 13, 2007
    Assignee: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot
  • Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
    Patent number: 7098211
    Abstract: The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: August 29, 2006
    Assignee: Artesian Therapeutics, Inc.
    Inventors: Gregory S. Hamilton, Harry Jefferson Leighton
  • Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
    Publication number: 20040242648
    Abstract: The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
    Type: Application
    Filed: October 7, 2003
    Publication date: December 2, 2004
    Applicant: ARTESIAN THERAPEUTICS, INC.
    Inventors: Gregory S. Hamilton, Harry Jefferson Leighton
  • CNS target modulators
    Publication number: 20040142972
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 22, 2004
    Applicant: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J.M. Mignot
  • Treatment of sleeping disorders using CNS sleep target modulators
    Publication number: 20030232839
    Abstract: The invention is directed to compositions used for treating sleep disorders. In addition, the invention provides convenient methods of treatment of a sleep disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of ester derivatized trazodone compounds for the treatment of sleep disorders.
    Type: Application
    Filed: January 21, 2003
    Publication date: December 18, 2003
    Applicant: Hypnion, Inc.
    Inventors: David G. Hangauer, Harry Jefferson Leighton, Dale M. Edgar
  • Treatment of CNS disorders using CNS target modulators
    Publication number: 20030187021
    Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.
    Type: Application
    Filed: October 16, 2002
    Publication date: October 2, 2003
    Applicant: Hypnion, Inc.
    Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J.M. Mignot
  • Fat accumulation-modulating compounds
    Publication number: 20030130343
    Abstract: The present invention pertains to compounds effective at modulating fatty acid or triglyceride accumulation by fat cells, such compounds having therapeutic potential as regulators of body mass and for the treatment of overweight individuals, obesity, and metabolic disorders.
    Type: Application
    Filed: August 8, 2002
    Publication date: July 10, 2003
    Applicant: AdipoGenix, Inc.
    Inventors: Michael John Stevenson, Harry Jefferson Leighton